Greater persistence and adherence to basal insulin therapy is associated with lower healthcare utilization and medical costs in patients with type 2 diabetes: a retrospective database analysis

被引:0
|
作者
Aroda, Vanita R. [1 ]
Nielsen, Nick [2 ]
Mangla, Kamal K. [2 ]
Multani, Jasjit [3 ]
Divino, Victoria [3 ]
Namvar, Tarlan [4 ]
Rajpura, Jigar [4 ]
机构
[1] Brigham & Womens Hosp, Endocrinol Diabet & Hypertens, Boston, MA 02115 USA
[2] Novo Nord A S, Bagsvaerd, Denmark
[3] IQVIA Inc, Falls Church, VA USA
[4] Novo Nordisk Inc, Plainsboro, NJ USA
关键词
Patient Compliance; Health Care Costs; Diabetes Mellitus; Type; 2; ECONOMIC OUTCOMES; FOLLOW-UP; MELLITUS; PREDICTORS; MANAGEMENT; PEOPLE; IMPACT; PEN;
D O I
10.1136/bmjdrc-2023-003825
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction We aimed to assess persistence and adherence to basal insulin therapy, their association with all-cause healthcare resource utilization (HCRU) and direct medical costs, and predictors of persistence and adherence in adults with type 2 diabetes.Research design and methods A retrospective cohort study was conducted with US adults with type 2 diabetes initiating basal insulin therapy between January 1, 2016, and December 31, 2018, using IQVIA PharMetrics Plus claims data. Persistence and adherence were assessed during 1 year post-initiation per previous definitions. Demographic/clinical characteristics were assessed during the 1 year pre-initiation. Inverse probability of treatment weighting (IPTW) was used to adjust for confounding variables. Post-IPTW, all-cause HCRU and direct medical costs were assessed during the first-year and second-year post-initiation by persistence and adherence status. Multivariable logistic regression was used to identify predictors of persistence and adherence.Results The final sample comprised 64,953 patients; 56.8% demonstrated persistence and 41.9% demonstrated adherence. Patients demonstrating persistence and adherence were significantly less likely to have a hospitalization than patients demonstrating non-persistence or non-adherence, respectively. In the second-year post-initiation, total mean all-cause direct medical costs per patient were lower for patients demonstrating persistence and significantly lower for patients demonstrating adherence. Prior use of both oral and injectable antidiabetic medication predicted persistence and adherence compared with patients with only prior oral antidiabetic medication use (persistence OR, 1.50 (95% CI, 1.44 to 1.57); adherence OR, 1.48 (95% CI, 1.42 to 1.55)).Conclusions Persistence and adherence to basal insulin was associated with fewer hospitalizations and lower direct medical costs.
引用
收藏
页数:12
相关论文
共 50 条
  • [1] Insulin adherence and persistence among Chinese patients with type 2 diabetes: a retrospective database analysis
    He, Xiaoning
    Chen, Liming
    Wang, Ke
    Wu, Haiya
    Wu, Jing
    PATIENT PREFERENCE AND ADHERENCE, 2017, 11 : 237 - 245
  • [2] Adherence and Persistence to Basal Insulin Therapy Is Associated with Decreased Health Care Utilization in Adults with Type 2 Diabetes
    Nielsen, Nick F.
    Aroda, Vanita R.
    Mangla, Kamal K.
    Divino, Victoria
    Namvar, Tarlan
    Rajpura, Jigar R.
    DIABETES, 2023, 72
  • [3] A RETROSPECTIVE DATABASE ANALYSIS OF PERSISTENCE WITH INSULIN IN PATIENTS WITH TYPE 2 DIABETES ADDING MEALTIME INSULIN TO A BASAL REGIMEN
    Kalsekar, A.
    Bonafede, M. M.
    Pawaskar, M. D.
    McGuffie, K.
    Torres, A.
    Kelly, K. R.
    Curkendall, S.
    VALUE IN HEALTH, 2009, 12 (07) : A413 - A413
  • [4] Insulin use and persistence in patients with type 2 diabetes adding mealtime insulin to a basal regimen: a retrospective database analysis
    Machaon M Bonafede
    Anupama Kalsekar
    Manjiri Pawaskar
    Kimberly M Ruiz
    Amelito M Torres
    Karen R Kelly
    Suellen M Curkendall
    BMC Endocrine Disorders, 11
  • [5] Insulin use and persistence in patients with type 2 diabetes adding mealtime insulin to a basal regimen: a retrospective database analysis
    Bonafede, Machaon M.
    Kalsekar, Anupama
    Pawaskar, Manjiri
    Ruiz, Kimberly M.
    Torres, Amelito M.
    Kelly, Karen R.
    Curkendall, Suellen M.
    BMC ENDOCRINE DISORDERS, 2011, 11
  • [6] Costs and patient outcomes associated with adherence to basal insulin therapy for people with type 2 diabetes
    Perez-Nieves, M.
    Boye, K. S.
    Kiljanski, J.
    Cao, D.
    Lage, M. J.
    DIABETOLOGIA, 2017, 60 : S343 - S344
  • [7] Predictors of Adherence and Persistence to Basal Insulin Therapy in Adults with Type 2 Diabetes
    Aroda, Vanita R.
    Nielsen, Nick F.
    Mangla, Kamal K.
    Wang, Yi
    Namvar, Tarlan
    Rajpura, Jigar R.
    DIABETES, 2023, 72
  • [8] Adherence to Insulin Pen Therapy Is Associated with Reduction in Healthcare Costs Among Patients with Type 2 Diabetes Mellitus
    Chandran, Arthi
    Bonafede, Machaon K.
    Nigam, Sonali
    Saltiel-Berzin, Rita
    Hirsch, Laurence J.
    Lahue, Betsy J.
    AMERICAN HEALTH AND DRUG BENEFITS, 2015, 8 (03): : 148 - 157
  • [9] Health care costs and medication adherence associated with initiation of insulin pen therapy in Medicaid-enrolled patients with type 2 diabetes: A retrospective database analysis
    Pawaskar, Manjiri D.
    Camacho, Fabian T.
    Anderson, Roger T.
    Cobden, David
    Joshi, Ashish V.
    Balkrishnan, Rajesh
    CLINICAL THERAPEUTICS, 2007, 29 : 1294 - 1305
  • [10] Adherence to Basal Insulin Therapy Among People with Type 2 Diabetes: A Retrospective Cohort Study of Costs and Patient Outcomes
    Perez-Nieves, Magaly
    Boye, Kristina S.
    Kiljanski, Jacek
    Cao, Dachung
    Lage, Maureen J.
    DIABETES THERAPY, 2018, 9 (03) : 1099 - 1111